Cite
HARVARD Citation
Barbour, S. et al. (2017). Integrated safety analysis of rolapitant with coadministered drugs from phase II/III trials: an assessment of CYP2D6 or BCRP inhibition by rolapitant. Annals of oncology. pp. 1268-1273. [Online].